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Abstract  Radiology  of  bone  lacunae  can  help  differentiate  between  smouldering  and  symp-
tomatic myeloma.  CT  seems  to  be  more  apt  for  this  purpose  than  a  standard  X-ray  but
appropriate  principles  must  be  applied  when  performing  and  reading  it.  Lesions  visible  in  an
MRI above  all  allow  myelomas  to  be  monitored  during  treatment.  Because  of  the  radiation  dose,
whole body  CT  must  be  performed  with  a  slice  thickness  of  2  mm,  increments  of  1.5  and  inten-
sity of  40  mAs.  It  should  be  read  associating  the  reading  of  the  axial  slices  with  reading  the
mean coronal  and  sagittal  projections  of  a  thickness  of  2  cm.  Whole  body  MRI  must  associate
T1-weighted  sagittal,  STIR  coronal  and  b-800  diffusion-weighted  axial  sequences.  Changes  in
the disease  correlate  with  changes  in  the  diffusion,  STIR  and  T1-weighted  images  interpreted
together. While  whole  body  CT  has  a  place  in  clinical  routine,  the  indication  for  whole  body  MRI
still needs  to  be  clariﬁed  and  has  yet  to  take  its  place  in  research  protocols.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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MM  Multiple  Myeloma
SMM  Smouldering  Multiple  Myeloma,  also  known  as  Asymptomatic  Multiple  Myeloma  or
Indolent  Myeloma
MGUS  Monoclonal  Gammopathy  of  Undetermined  Signiﬁcance
PPE  Plasma  Protein  Electrophoresis
FLC  Free  Light  Chain
ADC Apparent  Diffusion  Coefﬁcient
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Smouldering  multiple  myeloma:70  
P  Monoclonal  Protein
GPR Very  Good  Partial  Response
R  Complete  Response
R  Partial  Response
LP  Dose  Length  Product
ntroduction
adiological  exploration  of  plasma  cell  disease,  which  for
everal  decades  was  satisﬁed  with  standard  X-ray  explo-
ation  of  the  whole  skeleton,  seems  to  be  able  to  beneﬁt
rom  the  recent  advances  in  medical  imaging,  and  more  par-
icularly  from  whole  body  CT  scanning,  F-18  FDG  PET  and
hole  body  diffusion-weighted  MRI.  While  diagnosis  of  bone
esions  is  still  based  essentially  on  the  observation  of  bone
ysis,  inﬁltrations  seen  in  MRI  may  perhaps  be  of  use  for  mon-
toring  the  evolution  of  symptomatic  myelomas,  particularly
uring  treatment.  Apart  from  bone  fracture  and  compressive
omplications,  myeloma  poses  two  problems  for  radiology:
the  ﬁrst,  during  diagnosis,  is  recognizing  bone  lacunae,
which  very  often  deﬁne  the  symptomatic  nature  of  the
disease.  While  standard  X-rays  have  been  used  for  a  long
time,  whole  body  CT  is  now  playing  a  greater  and  greater
role  due  to  its  efﬁcacy  and  comfort  for  the  patient.  Var-
ious  studies  [1—4]  have  already  shown  its  usefulness  and
have  thoroughly  studied  the  radiation  dose  relative  to
standard  exploration.  However,  we  feel  that  the  methods
used  for  reading  it  and  the  signs  visible  should  be  clearly
set  out  in  order  to  optimise  its  performance  still  further;
the  second  problem,  for  monitoring  treatment,  is  using
an  imaging  examination  to  evaluate  the  efﬁcacy  of  the
treatment.  We  know  that  MRI,  like  a  PET  scan,  to  a  cer-
tain  extent  allows  changes  in  lesions  to  be  measured
during  treatment  [5—7]. Here  too,  it  would  be  useful  to
clarify  the  technique  and  the  signs,  and  evaluate  its  per-
formance.
To  provide  answers  to  these  two  radiological  problems,
e  carried  out  two  studies:
the ﬁrst  consisted  of  comparing  several  methods  of  read-
ing  whole  body  bone  scans  in  exploring  multiple  myeloma,
with  the  principal  objective  of  studying  the  concordance
between  three  methods  of  reading  these  scans  (axial
slices,  tomographic  reading  and  a  combination  of  the
two).  The  secondary  objective  was  to  study  the  inter-
examiner  (clinician/radiologist)  reproducibility  of  each
reading  method.  We  also  took  advantage  of  the  occasion
igure 1. Two-millimetre slices of femurs, MIP on the femurs, level 30
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to  evaluate  the  real  radiation  dose  received  by  the
patients,  a  third  objective;
the  second  study  consisted  of  comparing  the  changes  in
bone  signal  intensity  in  whole  body  MRI  with  the  evolution
of  laboratory  values  in  multiple  myeloma  (MM).  The  prin-
cipal  objective  was  to  study  the  changes  in  each  sequence
(diffusion-weighting,  STIR,  T1-weighting)  and  their  asso-
ciation  with  the  clinical  and  laboratory  evolution  of  the
condition.  The  secondary  objective  was  to  study  the  inter-
observer  reproducibility  of  analysis  of  the  signals  in  the
different  sequences.
aterials and method
e  performed  two,  single-centre,  retrospective  studies,
hich  had  been  approved  by  the  Rennes  University  Hospi-
als’  Ethics  Committee.
omparison of several methods of reading
hole body bone CT scans in exploring
ultiple myeloma
atients
he  patients  eligible  for  this  study  were  the  adults  being
ollowed  in  the  university  hospital  for  multiple  myeloma
ho  had  had  a  whole  body  bone  scan  between  01/07/2011
nd  01/05/2012.  The  patients  were  selected  on  the  imaging
erver  by  looking  for  all  those  who  had  had  a  whole  body  scan
uring  the  study  period.  The  ﬁles  were  then  consulted  indi-
idually  to  pick  out  the  cases  of  multiple  myeloma.  Between
1/07/2011  and  01/05/2012,  121  whole  body  bone  CT  scans
ere  performed,  including  60  to  explore  cases  of  multi-
le  myeloma.  One  patient  was  excluded  because  of  missing
ata.  In  the  end,  59  were  able  to  be  included  in  our  study
Fig.  1).  The  mean  age  of  the  patients  was  69.58  years,  with
 median  of  72  years.  The  male/female  sex-ratio  was  0.9.
he  indication  for  the  whole  body  bone  CT  scan  was  for  the
nitial  assessment  discovering  the  myeloma  in  68%  of  cases,
or  relapse  in  27%,  and  rarely  (3%)  for  other  indications.
iagnostic  criteria  of  MM  (IMWG  criteria  2006)  [8,9]0 window and width 1500 HU.
serum  monoclonal  immunoglobulin  greater  or  equal  to
30  g/l;
and/or
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• bone  marrow  plasma  cells  greater  or  equal  to  10%;
• absence  of  organ  lesions  (absence  of  CRAB  criteria).
Symptomatic  multiple  myeloma:
• serum  or  urinary  monoclonal  immunoglobulin;
• bone  marrow  plasma  cells  greater  or  equal  to  10%  or  plas-
macytoma;
• organ  lesions:  CRAB  criteria.
CRAB  criteria  (organ  or  tissue  lesions  secondary  to  mono-
clonal  plasma  cell  proliferation):
• hypercalcaemia:  blood  calcium  greater  than  2.75  mmol/l
or  greater  than  0.25  mmol/l  above  the  upper  limit  of  nor-
mal;
• renal  impairment:  serum  creatinine  greater  than
173  mol/l;
• anaemia:  haemoglobin  lower  than  normal  by  more  than
2  g/dl  or  haemoglobin  less  than  10  g/dl;
• bone  lesions:  lytic  or  osteoporotic  lesions  with  compres-
sion  fractures;
• symptomatic  hyperviscosity,  amyloidosis,  recurrent  bac-
terial  infection  (>  2  episodes  within  12  months).
Imaging  protocol
We  used  the  low  dose  protocol  proposed  by  Horger  [1]
(Table  1).Reading  the  CT  scan
CT  scans  were  read  by  a  radiologist  and  a  clinician.  The
analysis  focused  on  the  presence  of  bone  lysis,  deﬁned
Table  1  Low  dose  whole  body  CT  acquisition  protocol.
Position  Feet  ﬁrst
Dorsal  decubitus
Arms  alongside  the  body  or  on  the
abdomen  if  patient  is  too  wide  for  the  ﬁeld
Centring:  above  the  cranial  vault
Overview  Angle  of  view:  180◦ (frontal)
Length:  1530  mm
120  kv  30  Ma
FOV  500  mm
Spiral  Box
Above:  cranial  vault
Below:  knees
Parameters
Thickness:  2  mm
Increment:  1.5  mm
Constants:  120  kv  40  mAs
(50,  60  mAs  depending  on
morphology  +  removal  of  D-DOM  intensity
modulation)
Resolution:  standard
Collimation:  16*1.5
Pitch:  0.688
Rotation:  0.5  s
FOV:  500  mm
Filter:  sharp  (D)
CW:  600,  WW:  2000
Matrix:  512
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Digure 2. Twenty-millimetre slices of femurs, mean projection on
he femurs, level 300 window and width 1500 HU.
s  ‘punched  out’  osteolysis  with  no  border  of  perilesional
ondensation.  Six  anatomical  areas  were  evaluated:  the
kull,  spine,  pelvis,  ribs  and  sternum,  femur  and  humerus.
he  OSIRIX  viewer  was  used  for  reading.
The  three  reading  methods  used  were  as  follows:
2-mm  slices  were  read  in  MIP  giving  preference  to  the  axial
planes  (Fig.  1);
tomographic  reading  with  a  mean  projection  of  2  cm  thick-
ness  for  long  and  ﬂat  bones  with  a  preference  for  the
frontal  and  sagittal  planes  (Fig.  2);
a  combination  of  the  two  types  of  reading.
The  level  and  width  of  the  window  were  ﬁxed  for  the  two
rocedures  at  300  and  1500  HU.
The  number  of  lytic  lesions  was  recorded  both  globally
nd  by  zone  (0,  1,  2,  3,  4,  ≥  5  and  <  20,  and  ≥  20).
tatistical  study
he  primary  judgement  criterion  was  analysis  of  the  con-
ordance  between  the  three  reading  methods  (CT  slices,
omographic  reading,  and  a  combination  of  the  two)  for  the
verall  analysis  and  analysis  of  each  zone,  for  the  number
f  bone  lesions  seen  by  the  radiologist.
The  secondary  judgement  criterion  was  a  simple  or
etailed  analysis  of  inter-examiner  (radiologist/clinician)
eproducibility,  for  each  of  the  reading  methods,  for  the
verall  analysis  and  analysis  of  each  zone.A  mean  standard  deviation  of  the  DLPs  received  by  the
atients  was  calculated  and  the  min  and  max  values  of  the
LPs  identiﬁed.
Table  2  Interpretation  of  the  Cohen  kappa  values.
Interpretation
<  0  Disagreement
0.0—0.20  Very  little  agreement
0.21—0.40  Slight  agreement
0.41—0.60  Moderate  agreement
0.61—0.80  Strong  agreement
0.81—1.00  Virtually  perfect  agreement
172  
Concordance  between  the  different  methods  of  reading
and  inter-examiner  agreement  was  evaluated  using  Cohen’s
kappa  coefﬁcient  using  the  values  given  below  [10]  (Table  2).
Evaluation of the contribution made by whole
body MRI for monitoring myeloma
Patients
The  patients  eligible  for  this  study  were  adults  being  fol-
lowed  in  the  university  hospital  for  multiple  myeloma
who  had  had  at  least  two  whole  body  MRIs  with  diffu-
sion  sequences  for  monitoring  their  MM.  The  patients  were
selected  on  the  imaging  server  by  looking  for  all  those
who  had  had  two  whole  body  MRIs  with  diffusion  sequences
between  27/10/2008  and  31/08/2011.  The  date  when  the
ﬁrst  whole  body  MRI  with  diffusion  sequences  was  performed
in  a  multiple  myeloma  context  in  the  university  hospital
was  27/10/2008,  and  31/08/2011  was  the  date  when  we
selected  our  population.  We  then  consulted  the  clinical  ﬁles
of  all  these  patients  to  retain  only  patients  being  followed
for  multiple  myeloma.
Fifty-four  patients  were  included  in  our  study,  24  men
(44.4%)  and  30  women  (55.6%).  The  mean  age  at  diagnosis
was  64  years,  with  extremes  ranging  from  40  to  92  years.
Forty-eight  patients  had  symptomatic  MM,  ﬁve  had  SMM
and  one  presented  a  solitary  plasmacytoma.  Distribution  in
terms  of  the  type  of  monoclonal  protein  produced  was  as
follows:  for  the  symptomatic  MMs,  there  were  26  IgG,  14
IgA,  one  IgM,  six  light  chain  myelomas  and  one  non-secreting
myeloma.  For  the  SMM,  the  monoclonal  protein  implicated
was  IgG  in  four  cases  and  free  light  chains  in  one  case.  In
all,  the  monoclonal  protein  implicated  was  IgG  in  56%  of  the
cases,  IgA  in  26%,  IgM  in  1.8%,  FLC  in  13%,  and  none  of  these
in  1.8%  of  cases.  The  main  clinical  symptoms,  laboratory  test
values  and  radiological  changes  presented  by  the  patients  on
diagnosis  are  shown  in  Table  3.  Bone  lesions  preponderated,
with  two  thirds  of  the  patients  having  bone  pain  and  almost
as  many  with  radiological  bone  lesions.
Between  the  two  evaluations,  20  patients  (37%)  were
simply  monitored,  while  34  (63%)  received  one  or  more  lines
of  treatment  for  their  MM.  The  treatment  received  was  as
follows:  a  single  line  of  chemotherapy  in  29  patients,  with
Table  3  Clinical,  laboratory  and  radiological  signs  pre-
sented  by  patients  on  diagnosis.
Clinical  or  paraclinical  signs  and
symptoms
Number  of  patients
concerned
n =  54  (%)
Alteration  in  general  condition  19  (35.2)
Bone  symptoms  (pain,  fractures)  36  (66.7)
Spinal  cord  compression  2  (3.7)
Repeated  infections  3  (5.5)
Hyperviscosity  syndrome  1  (1.8)
Clinical  signs  of  hypercalcaemia  1  (1.8)
Anaemia  (haemoglobin  <  10  g/dl) 12  (22.2)
Renal  impairment  (serum
creatinine  level  >  173  mol/l)
3 (5.6)
Hypercalcaemia  >  2.75  mmol/l 4  (7.4)
Bone  lesions  on  X-ray  images  34  (63)
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n  additional  stem  cell  transplant  in  ﬁve  patients,  two  lines
f  chemotherapy  in  three  patients  and  three  lines  in  two
atients.  Several  therapeutic  regimens  were  used:  lenalino-
ide  alone  (n  =  11),  lenalinomide/dexamethasone  (n  =  10),
elphalan/prednisone/thalidomide  (n  =  9),  melphalan/
rednisone/bortezomib  (n  =  4),  bortezomib/dexamethasone
n  =  5),  bortezomib/thalidomide/dexamethasone  (n  =  3),
thers  (Caelyx-Endoxan,  Revlimid-Medrol,  BVD,  Velcade-
aelyx)  (n  =  4).  The  mean  period  of  time  between  the  two
RI  procedures  for  the  same  patient  was  313  days  (median
78  days)  with  extremes  ranging  from  52  to  801  days.
he  median  length  of  time  between  the  whole  body  MRI
ith  diffusion-weighted  sequences  and  the  clinical  and
aboratory  evaluation  was  2  days,  with  extremes  ranging
rom  0  to  36  days.
MWG  2006  criteria  for  the  rate  of  evolution  of  the
isease [9,11]
isease  progression:  more  than  25%  increase  in  at  least  one
f  the  following  aspects:
serum  MP  (increase  ≥  5  g/l);
urinary  MP  (increase  ≥  200  mg/24  h);
in  the  absence  of  measurable  serum  or  urinary  MP:
difference  between  the  involved  and  non-involved  FLC
(increase  ≥  100  mg/l);
bone  marrow  plasma  cells  (and  ≥  10%  plasma  cells);
appearance  of  new  bone  lesions  or  soft  tissue  plasmacy-
tomas,  or  increase  in  size  of  pre-existing  lesions;
appearance  of  hypercalcaemia  (corrected  blood  cal-
cium  >  11.5  mg/100  ml).
Stable:  absence  of  progression  criteria  or  response.
Partial  response  (PR):
reduction  greater  or  equal  to  50%  in  serum  MP  and  reduc-
tion  greater  or  equal  to  90%  in  urinary  MP  (or  urinary
MP  <  200  mg/24  h);
in  the  absence  of  measurable  MP,  reduction  greater  or
equal  to  50%  in  the  difference  between  involved  and  non-
involved  FLC;
if the  MP  and  FLC  are  not  measurable,  reduction  greater
or  equal  to  50%  in  bone  marrow  plasma  cells,  on  condition
that  they  were  initially  greater  or  equal  to  30%;
reduction  greater  or  equal  to  50%  in  the  size  of  soft  tissue
plasmacytomas.
Very  Good  Partial  Response  (VGPR):
serum  and  urine  IF  positive  but  electrophoresis  negative
or;
reduction  greater  or  equal  to  90%  in  the  serum  MP  and
urinary  MP  less  than  100  mg/24  h;
if the  MP  is  not  measurable,  reduction  greater  than  90%
between  the  involved  and  non-involved  FLC.
Complete  Response  (CR):
negative  blood  and  urinary  IF;
disappearance  of  soft  tissue  plasmacytomas;
bone  marrow  plasma  cells  less  than  5%;
if the  disease  is  only  measurable  by  the  FLC,  normal
kappa/lambda  ratio.
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Table  4  Whole  body  MRI  protocol  including  T1-weighted,  STIR  and  diffusion-weighted  sequences.
T1  TSE  iPAT  STIR  Diffusion  (DWIBS)
Plane  Sagittal
Cervical,  thoracic,  lumbar
spine
Coronal
Whole  body,  from  the  cranial
vault  to  mid-thigh
Axial
Whole  body,  from  the
cranial  vault  to  mid-thigh
Number  of  steps  2  3  6
TR  (ms) 560  7370  10,900
TE  (ms) 11 58 75
TI (ms) X 150 170
FOV  (mm/step) 360 500 500
Slice  thickness  (mm)  3  6  4
Number  of  slices  12  30  40
Bandwidth  (Hz/pixel)  130  277  1302
NEX  2  1  3
b  value  b  =  800  s/mm2
pathological  signal  =  T1-weighted  hypointensity  (H)  if  the
spine/disc  signal  ratio  less  than  1.3  (Fig.  3);
• with  STIR:  the  thoracic  and  lumbar  spine  signal  was
analysed  by  comparing  it  with  the  signal  from  psoas  mus-
cles:  normal  signal  (N)  if  the  spine/psoas  signal  ratio
less  or  equal  to  2,  pathological  signal  =  STIR  hyperinten-
sity  (H)  with  a spine/psoas  signal  ratio  greater  than  2
(Fig.  4);
• with  diffusion-weighting:  the  thoracic  and  lumbar  spine
signal  was  analysed  by  comparing  it  with  the  signal  from
the  kidneys:  normal  signal  (N)  if  there  is  no  or  little  sig-
nal  from  the  spine  with  a  spine/kidney  ratio  less  or  equal
to  1,  pathological  signal  =  diffuse  hyperintensity  (H)  of
the  spine  with  a spine/kidney  signal  ratio  greater  than
1  (Fig.  5).
By  analysing  the  three  sequences,  four  stages  of  diffuse
bone  marrow  inﬁltration  could  be  deﬁned:  normal,  slight,
moderate  or  severe  (Table  5).
For  focal  lesions:
• a  focal  lesion  was  deﬁned  as  a  nodular  lesion  which
was  hypointense  with  T1-weighting,  hyperintense  with
STIR  and/or  hyperintense  with  b-800  diffusion-weighting
(Fig.  6a  and  b);
• the number  of  focal  lesions  classiﬁed  as  less  than  ﬁve,
ﬁve  to  20  or  greater  than  20  according  to  the  Salmon  and
Durie  plus  staging  system  [13]  was  noted  for  each  MRI.  The
most  voluminous  focal  lesion  was  accurately  described
for  objective  monitoring:  site,  size  (large  axis)  and  signal
intensity.
Table  5  Stages  of  diffuse  bone  marrow  inﬁltration.
Signal
Stage  of  inﬁltration  T1  STIR  Diffusion
Normal  N  N  NFigure 3. Normal (a) and pathological (b) bone marrow signals in
T1-weighted sequence.
MRI  protocol
All  our  images  were  produced  on  the  same  MRI  machine
(Siemens  Magnetom  Symphony  1.5T,  Siemens  Medical  Solu-
tions,  Erlangen,  Germany).  The  same  protocol  was  used  as
in  a  comparative  study  of  the  signal  in  MRI  and  PET-CT
[12].  Each  examination  was  comprised  of  three  sequences
(Table  4).
Reading  the  MRIs
The  MRIs  for  this  study  were  reread  independently  by  two
senior  radiologists  who  were  unaware  of  the  patient’s  clin-
ical  data.  The  signs  used  were  also  the  same  as  those  used
in  the  previous  study  [12]. The  signal  analysis  criteria  were
as  follows:For  diffuse  bone  marrow  inﬁltration:
• with  T1-weighting:  the  spinal  signal  was  compared  with
that  from  the  intervertebral  discs:  normal  signal  (N)
if  the  spine/disc  signal  ratio  greater  or  equal  to  1.3,
Slight  N  N  H
Moderate  N  H  H
Severe  H  H  H
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Figure 4. Normal (a) and pathological (b) signal in STIR sequence.
Figure 5. Normal bone marrow signal (a) and diffuse bone marrow hyperintensity (b) with b-800 diffusion-weighting.
Figure 6. Patient with more than 20 focal lesions: a: T1-weighted sequence; b: STIR sequence; c: STIR-diffusion-weighted fusion.
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Table  6  Evaluation  of  overall  evolution  in  MRI  (adapted
from  RECIST  criteria).
Complete  response  Disappearance  of  the  diffuse
bone  marrow  inﬁltration
(normal  signal)
And  disappearance  of  the  focal
lesions  including  the  most
voluminous
Partial  response Improvement  in  the  diffuse
inﬁltration
And/or  reduction  in  the  number
of  focal  lesions
And/or  reduction  in  the  size  of
the  most  voluminous  focal  lesion
Stable  disease No  criteria  either  for  a  response
or  for  disease  progression
Disease  progression  Aggravation  of  the  diffuse  bone
marrow  inﬁltration
And/or  increase  in  the  number
of  focal  lesions
And/or  increase  in  the  size  of
the  most  voluminous  focal  lesion
Table  7  Number  of  lesions  seen  with  the  three  reading
methods.
%  of  CT  scans  with  diagnosis  of  lesions
Slice
method
Tomographic
method
Combined
method
Overall  analysis  71  66  88
Skull  50  54  69
Spine  29  10  37
Pelvis  34  17  47
Ribs  and  sternum  18  17  37
Humerus 27  18  59
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preferable  for  the  skull  (Table  8).MRI  rate  of  evolution  criteria  selected
For  each  T1-weighted,  STIR  and  diffusion-weighted
sequence  the  MRIs  were  compared  two  by  two  for  diffuse
bone  marrow  inﬁltration,  the  number  of  focal  lesions
and  evolution  of  the  most  voluminous  focal  lesion,  and
ﬁnally,  overall  evolution  was  assessed  based  on  these  three
parameters.
To  deﬁne  overall  evolution,  we  considered  the  Response
Evaluation  Criteria  In  Solid  Tumours  (RECIST)  imaging  recom-
mendations  (revised  version  1.1),  which  deﬁne  four  response
stages  for  monitoring  solid  tumours  by  imaging:  complete
response,  partial  response,  stable  disease,  progression  of
the  disease  [14,15].  We  adapted  these  criteria  to  multiple
myeloma  (Table  6).
In  diffuse  inﬁltrations  where  focal  lesions  cannot  be
counted,  we  considered  that  the  evolution  of  diffuse  inﬁltra-
tion  towards  focal  lesions  corresponded  to  regression  of  the
lesion.  In  contrast,  a  change  from  focal  lesions  towards  dif-
fuse  inﬁltration  was  considered  as  progression  of  the  lesion. s
Table  8  Concordance  between  the  three  reading  methods.
Weighted  kappa  concordance  results  (lesion/no  lesion)
Slice/Tomographic  
Overall  analysis  0.59  
Skull  0.63  
Spine  0.23  
Pelvis  0.49  
Ribs  and  sternum  0.59  
Humerus 0.67  
Femur  0.58  Femur 37 25  71
For  the  statistical  analysis,  the  overall  MRI  evolution  was
impliﬁed  into  three  groups:  response  (grouping  together
artial  and  complete  responses),  stability  and  progression.
tatistical  study
oncordance  of  the  readings  by  the  two  radiologists  on  each
he  type  of  MRI  sequence.
Concordance  between  the  clinical  and  laboratory  value
volution  and  the  MRI  response  on  each  of  the  sequences
nd  on  the  combinations  of  them.
The  concordance  studies  were  performed  using  Cohen’s
eighted  kappa  method.
esults
T scan
he  slice  method  allowed  more  lesions  to  be  seen  than
he  tomographic  method.  However,  combination  of  the  two
eading  methods  increased  the  number  of  lesions  seen  for
ll  locations  and  particularly  for  the  humerus  and  femur
Table  7).
Study  of  the  concordance  between  these  three  reading
ethods  showed  that  the  slice  method  was  preferable  for
he  spine  and  pelvis.  The  combined  method  was  essential
or  the  femur  and  humerus.  The  tomographic  method  wasStudy  of  the  agreement  between  clinician  and  radiologist
howed  that  this  was  poor  to  moderate  (Table  9).
Tomographic/Combined  Slice/Combined
0.47  0.55
0.51  0.41
0.22  0.56
0.27  0.51
0.51  0.56
0.28  0.23
0.21  0.37
176  
Table  9  Concordance  between  clinician/radiologist
interpretation  for  the  three  types  of  reading.
Clinician/radiologist  weighted  kappa  concordance
results  (lesion/no  lesion  analysis)
Tomographic
method
Slice
method
Combined
method
Overall 0.51  0.41  Ns
Skull  0.57  Ns  Ns
Spine 0.36  0.48  0.37
Pelvis 0.61  0.74 0.59
Rib 0.67  0.60 0.56
Humerus 0.79  0.44 0.41
Femur  0.75  0.34  0.23
Table  10  Inter-observer  agreement  depending  on  the
sequence.
Sequence Weighted  kappa
T1  0.70
STIR  0.66
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ration  continues  to  prefer  conventional  X-rays  [8].  DespiteDiffusion  0.57
Finally,  in  our  study,  the  mean  DLP  was  392  mGy*cm  with
 standard  deviation  of  68  mGy*cm.  The  minimum  and  max-
mum  values  were  313  and  655  mGy*cm,  respectively.
RI
nter-observer  agreement  proved  to  be  quite  high  in  each
ype  of  sequence,  but  decreased  slightly  between  T1-
eighting,  STIR  and  diffusion-weighting  (Table  10).
Concordance  between  clinical  and  laboratory  value  evo-
ution  and  the  evolution  of  the  MRI  signal  was  poor  for
1-weighting  and  moderate  for  the  other  signals,  increasing
lightly  between  T1-weighting,  STIR,  diffusion-weighting,
1-STIR  and  T1-STIR-diffusion  combinations  (Table  11).
iscussion
T in the diagnosis of symptomatic multiple
yeloman  myeloma,  whole  body  CT  acquisition  allows  the  entire
keleton  to  be  explored  while  the  patient  lies  for  a
ew  minutes  on  a  mattress,  which  is  indisputably  more
t
d
w
Table  11 Concordance  between  clinical  and  laboratory  value
considered.
Concordance  between  clinical  &  laboratory  values  and  T1  
Concordance  between  clinical  &  laboratory  values  and  STIR  
Concordance  between  clinical  &  laboratory  values  and  Diffusio
Concordance  between  clinical  &  laboratory  values  and  T1—STIR
Concordance  between  clinical  &  laboratory  values  and  T1—STIRR.  Duvauferrier  et  al.
omfortable  for  him  or  her  than  having  several  incidences
aken  on  a  standard  radiology  table.  The  radiation  dose,
hich  is  twice  that  of  an  ordinary  standard  examination,
eems  perfectly  tolerable  given  the  indication  and  the  ben-
ﬁt  expected  [1].  Kropil’s  recent  study  [3]  showed  that
hole  body  CT  gave  better  results  than  standard  X-rays  for
nalysing  lytic  lesions  on  the  spine,  pelvis  and  rib  cage.  The
se  of  CT  scans  may  thus  lead  to  therapeutic  management
f  severe  myelomas  being  modiﬁed.  This  study,  performed
ith  a  64-slice  scanner,  gave  radiation  doses  comparable
ith  ours  (DLP  408  mGy*cm  SD  57),  a little  more  than
wice  the  radiation  dose  of  the  standard  X-ray  (4.8  versus
.7  mSv).  Another  recent  study  by  Gleeson  produced  similar
esults.
Given  the  quality  of  the  CT  explorations  obtained,  we
elt  it  was  difﬁcult  from  an  ethical  point  of  view  to  com-
are  standard  X-rays  and  CT  scans.  This  is  why  in  this  study
e  envisaged  comparing  and  combining  the  reading  of  slices
nd  reading  the  CT  scan  ‘tomographically’,  which  in  itself
eemed  to  optimise  what  conventional  X-rays  could  offer.
e  rapidly  realised  the  usefulness  of  the  two  methods  of
eading,  in  as  far  as  the  number  of  lesions  seen  was  greater
hen  combining  the  two  reading  techniques  compared  with
eading  each  technique  in  isolation.  There  was  good  con-
ordance  between  the  lesions  seen  with  the  tomographic
nd  slice  methods,  apart  from  in  the  spine.  The  tomographic
ethod  proved  inadequate  compared  with  the  slice  method
or  the  spine  and  pelvis.  As  to  the  combined  method,  it  is
equired  for  the  limbs,  since  neither  the  tomographic  nor
he  slice  method  concurred,  in  isolation,  with  the  combined
ethod.  Finally  for  the  skull,  we  thought  that  the  tomo-
raphic  model  was  easier  to  read  and  probably  gave  better
esults.
At  ﬁrst  sight,  we  were  worried  by  the  discordance
etween  clinician  and  radiologist.  However,  its  analysis
howed  that  there  was  nevertheless  good  concordance  for
he  tomographic  analysis  apart  from  in  the  spine,  whereas
his  was  much  lower  in  the  slice  and  combination  methods.
e  interpreted  this  as  insufﬁcient  training  in  bone  pathol-
gy  signs  in  slices.  It  was  not  the  case  for  the  tomographic
nalysis  because  the  latter  was  very  close,  in  terms  of  signs,
o  analysis  of  standard  X-rays,  which  the  clinician  had  per-
ormed  before.
Although  whole  body  CT  scans  could,  in  our  opinion,
eplace  examination  of  the  skeleton  because  of  its  speed  and
etter  patient  tolerance,  the  most  recent  consensus  decla-his,  we  have  modiﬁed  our  exploration  strategy  and  aban-
oned  the  use  of  standard  X-rays  in  myeloma  in  favour  of
hole  body  CT  scans.
 evolution  and  MRI  evolution  depending  on  the  sequences
Weighted  kappa
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MRI in monitoring myelomas
The  signs  in  the  three  (T1-weighted,  STIR,  diffusion-
weighted)  sequences  and  their  combination  have  been
validated  in  a  previous  study  [12]  which  compared  MRI  and
PET-CT.  The  present  study  was  essentially  interested  in  the
evolution  of  the  images  compared  with  the  clinical  evolution
and  changes  in  laboratory  values.  It  showed  good  inter-
observer  agreement  and  clearly  indicated  the  value  of  each
of  the  parameters,  taken  singly  or  combined,  in  analysing
the  evolution  of  the  myeloma.  It  can  therefore  be  said  that
there  is  moderate  to  good  concordance  of  the  evolution  of
the  MR  images  with  the  clinical  evolution  and  changes  in
laboratory  values  and  this  improves  if  T1-weighting,  STIR,
diffusion-weighting,  and  T1-STIR  and  T1-STIR-diffusion  com-
binations  are  considered.  The  analysis  of  particular  cases
(see  our  clinical  cases  at  the  end  of  the  paper)  even  shows
that  MRI  correlates  better  with  clinical  evolution  than  do
laboratory  values.
Two  recent  studies  have  evaluated  the  correlation
between  evolution  in  whole  body  MRIs  (without  diffusion
sequences)  and  response  to  treatment  in  patients  treated
for  MM  receiving  stem  cell  transplants.  The  ﬁrst  was  a  ret-
rospective  study  [5]  on  100  patients  treated  for  MM  in  whom
two  whole  body  MRIs  were  performed,  at  the  beginning  of
treatment  and  3  to  6  months  after  autologous  stem  cell
transplantation  (ASCT).  This  study  showed  low  correlation
between  clinical  and  laboratory  value  evolution  (IURC)  and
evolution  in  the  whole  body  MRI  (kappa  0.32,  CI  95%  0.15  to
0.49).  The  second  study  was  prospective  [6]  and  included
33  patients  with  MM  who  had  had  stem  cell  transplanta-
tion.  In  these  patients,  two  successive  whole  body  MRIs  were
performed  following  the  stem  cell  transplant,  each  time
coupled  with  haematological  evaluation.  Statistical  analy-
sis  found  moderate  concordance  between  evaluation  of  the
evolution  of  the  disease  using  the  classic  laboratory  crite-
ria  and  MRI  (kappa  0.51,  CI  95%  0.19  to  0.82).  In  these  two
studies,  the  authors  emphasize  the  potential  usefulness  of
diffusion  MRI  for  evaluating  response  to  treatment.  In  our
series,  the  concordance  we  found  between  the  clinical  and
laboratory  value  evolution  and  whole  body  MRI  was  bet-
ter  than  in  the  study  by  Hillengass  et  al.  [5]  but  similar  to
that  found  by  Bannas  et  al.  [6].  It  is  therefore  difﬁcult  to
draw  conclusions  about  the  usefulness  of  diffusion-weighted
sequences  just  from  these  results.  To  our  knowledge,  only
one  study  has  been  published  to  date  evaluating  whole  body
MRI  with  diffusion-weighted  sequences  for  monitoring  the
response  to  treatment  in  MM.  This  prospective  study  by
Horger  et  al.  [7]  enrolled  12  adult  patients  with  symptomatic
MM  (Salmon  and  Durie  classiﬁcation  stage  III).  Two  whole
body  MRIs  with  diffusion-weighted  sequences,  coupled  with
a  standard  haematological  evaluation,  were  performed  in
these  patients  at  the  start  and  about  three  weeks  after  the
beginning  of  treatment  (a  mean  of  23  days,  extremes  8—37).
The  MRIs  were  interpreted  with  measurement  of  the  appar-
ent  diffusion  coefﬁcient  (ADC).  Eleven  patients  responded
to  the  treatment,  but  the  twelfth  was  a  non-responder.
The  evolution  of  the  ADC  correlated  with  the  evolution  in
the  haematological  values  in  all  the  patients:  in  all  the
responders  an  increase  in  the  ADC  was  seen,  in  the  non-
responder,  the  mean  ADC  decreased.  Analysis  of  the  signal
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ntensity  with  T1-weighting  and  STIR  did  not  provide  a  reli-
ble  evaluation  of  the  response  to  treatment  in  the  short
erm.
In  our  study,  there  was  a  long  period  of  time  between  the
wo  MRIs,  a  mean  of  313  days.  The  usefulness  of  diffusion-
eighted  MRI  would  be  precisely  for  early  evaluation  of
he  response  to  treatment,  before  T1-weighted  and  STIR
equences,  which  take  several  months  to  show  any  modiﬁ-
ation,  have  had  the  time  to  change.  In  the  study  by  Horger
t  al.  [7]  the  two  MRIs  with  diffusion-weighted  sequences
ere  performed  at  a  maximum  interval  of  37  days,  modiﬁ-
ation  in  the  diffusion  signal  was  seen,  and  the  T1-weighted
nd  STIR  sequences  did  not  seem  to  be  reliable  for  short-
erm  monitoring.  Sommer  et  al.  [16]  compared  the  signal
n  whole  body  MRIs  with  diffusion-weighted  sequences,  in
1  patients  with  plasma  cell  dyscrasia,  with  the  concentra-
ion  of  the  serum  monoclonal  component.  The  patients  were
ivided  into  two  groups  depending  on  their  serum  mono-
lonal  component  value:  high  (greater  than  20  g/l)  or  low
less  than  20  g/l).  A  signiﬁcant  difference  in  the  mean  ADC
f  the  focal  lesions  in  MRI  was  observed  between  these
wo  groups.  In  their  study  comparing  diffusion-weighted  MRI
nd  histology  in  56  patients  with  plasma  cell  dyscrasia  (40
ymptomatic  MMs,  13  SMMs,  one  plasmacytoma,  two  MGUS),
illengass  et  al.  [17]  found  a  positive  correlation  between
DC  and  bone  marrow  plasma  cell  level  and  between  ADC
nd  vascular  density  in  the  osteomedullary  biopsy.  In  this
ame  study,  Hillengass  et  al.  evaluated  15  of  the  patients
ith  a  symptomatic  MM  before  and  after  treatment.  Of  these
5  patients,  after  treatment  12  presented  a  VGPR  or  a  CR,
wo  a  PR  and  the  disease  was  stable  in  the  last.  The  mean
DC  had  decreased  signiﬁcantly  before  and  after  treatment.
his  clearly  shows  that  the  diffusion-weighted  MRI  signal
volves  with  treatment  of  the  MM.  The  time  between  the
wo  MRIs  in  these  15  patients  was  not  speciﬁed  in  the  paper.
he  concentration  of  the  serum  monoclonal  component  and
he  degree  of  bone  marrow  plasmacytosis  come  within  the
esponse  to  treatment  criteria  for  MM;  the  concentration  of
he  monoclonal  component  is  even  the  principle  monitoring
arameter.  The  fact  that  these  two  parameters  are  corre-
ated  with  diffusion-weighted  MRI  signal  intensity  (and  with
he  ADC)  clearly  shows  the  usefulness  of  diffusion-weighted
RI  in  monitoring  patients  with  MM.  In  another  study  [18],
illengass  observed  diffusion-weighted  MRI  hyperintensity
n  SMMs,  which  prevents  the  use  of  the  MRI  results  for  diag-
osing  symptomatic  myeloma  even  if  the  presence  of  this
yperintensity  is  probably  an  indicator  of  a  poor  prognosis.
Unlike  Sommer  [16]  and  Hillengass  [17], we  did  not
nclude  the  ADC  in  our  signs  but  preferred  to  use  a
emi-quantitative  diffusion  measurement  at  b-800  rather
han  essentially  quantitative  measurement,  because  of
his  sequence’s  signal  performance.  Indeed,  the  literature
19,20]  suggests  that  the  correlation  of  the  ADC  with  bone
arrow  cellularity  is  biphasic,  with  an  initial  increase  in  sig-
al  intensity  for  high  b  values  and  in  the  ADC,  when  the  fat
ells  of  the  yellow  marrow  are  gradually  replaced  by  the  ele-
ents  of  normal  red  marrow  and/or  tumour  cells.  But  once
ll  the  fat  cells  in  the  bone  marrow  have  been  replaced,  a
eduction  in  ADC  values  is  seen  (while  the  signal  intensity  on
mages  with  a high  b  value  continues  to  progress).  It  seems
hat  changes  in  signal  intensity  on  images  with  a high  b  value
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w78  
ore  faithfully  reﬂect  the  changes  in  cellularity  than  do  ADC
alues.
Our  ﬁrst  study  comparing  MRI/PET-CT  signals  [12]  and  this
tudy  on  evolution  of  the  signal  seem  to  conﬁrm  this  use  of
he  b-800  diffusion-weighted  signal.  However,  modiﬁcations
n  the  diffusion-weighted  signal  should  be  interpreted  with
aution  when  used  in  early  monitoring  of  treatment,  not  the
ase  in  our  study.  Tissue  oedema  secondary  to  radiotherapy
ay  appear  in  fact  as  an  increase  in  signal  at  b-800.  The
ame  applies  when  myelomas  are  successfully  treated  when
here  is  liquefaction  necrosis  of  lesions.  This  increase  in
esion  signal  intensity  on  the  images  with  a  high  b  value  (with
orrespondingly  increased  ADC  values)  indicates  their  high
ater  content  and  is  what  is  known  as  T2  ‘shine-through’
20]. Consequently,  to  avoid  errors  arising  from  visual  eval-
ation  of  high  b  signal  intensity,  it  is  essential  to  correlate
he  results  of  high  b  value  images  with  the  ADC  maps  and
onventional  images  particularly  with  T2-weighting:  early
ncrease  in  signal  in  STIR  and  at  b-800  indicates  lesion  necro-
is  and  therefore  has  the  same  signiﬁcance  as  reduction  in
he  signal  at  b-800.
onclusion
hole  body  CT  plays  an  important  role  in  exploring  myelo-
as.  Its  radiation  dose  has  become  compatible  with  clinical
ractice  and  the  comfort  for  the  patient  is  undeniable  when
ompared  with  producing  many  standard  X-ray  images.  Bone
acunae  are  essential  for  classifying  symptomatic  myelomas
nd  the  efﬁcacy  of  CT  scans  is  becoming  more  and  more
idely  acknowledged.  CT  allows  slice  reading,  important
or  the  spine  and  pelvis,  to  be  combined  with  ‘tomographic’
eading  which  removes  any  ambiguity  from  the  sometimes
ermeative  appearance  of  long  bones.  The  reading  princi-
les  and  the  signs  involved  must  however  be  more  widely
ublished  to  ensure  reproducibility  of  the  interpretation  of
he  examination.
The  lesions  visible  with  MRI  seem  to  be  useful  for  monitor-
ng  myeloma  under  treatment.  Our  study  shows  that  whole
ody  MRI  must  combine  T1-weighted  sagittal,  STIR  coro-
al  and  b-800  diffusion-weighted  axial  sequences.  However,
urther  studies  are  needed  to  determine  the  practical  use-
ulness  of  the  changes  in  these  signals  during  evolution  of
he  disease,  particularly  during  treatment,  relative  to  the
aboratory  examinations  currently  performed.
TAKE-HOME  MESSAGES
• Whole  body  CT  has  an  important  role  in  the  diagnosis
of  myeloma.  The  radiation  dose  it  involves  is
acceptable  and  patient  comfort  is  improved.
• Bone  lacunae  are  essential  for  classifying
symptomatic  myelomas  and  the  efﬁcacy  of  CT
scans  is  more  and  more  widely  acknowledged.  CT
allows  slice  reading,  important  for  the  spine  and
pelvis,  to  be  combined  with  ‘tomographic’  reading
which  removes  any  ambiguity  from  the  sometimes
permeative  appearance  of  long  bones.
• Lesions  visible  with  MRI  appear  to  be  useful  for
monitoring  myelomas.
r
m
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fR.  Duvauferrier  et  al.
• Whole  body  MRI  must  combine  T1-weighted
sagittal,  STIR  coronal  and  b-800  diffusion-weighted
sequences.
• Further  studies  are  needed  to  determine  the
practical  usefulness  of  the  changes  in  these  signals
during  evolution  of  the  disease,  particularly  during
treatment,  relative  to  the  laboratory  examinations
currently  performed.
linical case
linical case illustrating the usefulness of a  CT
can in looking for lacunae
e  present  here  the  case  of  a  patient,  Mrs  T.  who  has  basi-
ally  small  lesions.  The  signs  of  the  small  lytic  images  should
e  analysed  using  both  reading  methods  (Figs.  7—10), lesions
n  the  spongy  bone  are  difﬁcult  to  analyse  in  slices,  and
e  need  to  look  for  endosteal  resorption.  With  the  ‘tomo-
raphic’  method,  these  small  lacunae  appear  as  ‘punched
ut’  lacunae  or  have  a  permeative  or  ‘moth-eaten’  appear-
nce  when  they  are  numerous.
linical cases illustrating the usefulness of MRI
or monitoring the evolution of myeloma
e  present  the  clinical  histories  of  three  patients  which  we
hink  well  illustrate  the  usefulness  of  diffusion-weighted  MRI
or  monitoring  MM.
ase  1
he  ﬁrst  case  concerned  Mr  A.  whose  disease  evolved
avourably  with  treatment  (Fig.  11):  in  this  79-year-old
atient,  the  chance  discovery  of  hyperproteinaemia  led  to
he  diagnosis  of  an  IgG  lambda  MM  at  the  end  of  August
009,  classed  as  symptomatic  owing  to  the  existence  of
naemia  (haemoglobin  8.9  g/dl).  A  ﬁrst  whole  body  MRI  with
iffusion-weighted  sequences,  performed  on  01/09/2009,
ound  severe  myelomatous  involvement  with  innumerable
ocal  lesions.  It  should  be  noted  that  the  standard  X-ray
eport  at  the  time  was  negative  (a:  T1-weighted,  b:  STIR,
:  diffusion-weighted,  d:  STIR-diffusion-weighted  fusion).
r  A.  was  treated  with  lenalinomide/dexamethasone.  A
econd  whole  body  MRI  with  diffusion-weighted  sequences
as  performed  on  06/11/2009,  i.e.  after  two  courses  of
reatment.  Mr  A.  then  presented  a  partial  response  to  the
reatment  since  the  monoclonal  peak  had  reduced  from  an
nitial  value  of  65.6  g/l  to  9.4  g/l.  On  this  second  MRI,  there
as  already  a considerable  reduction  in  the  size  and  number
f  the  initial  lesions  (e—h).  After  seven  courses  of  treat-
ent,  the  patient  showed  a  complete  response  with  normal
PE,  negative  serum  and  urinary  immunoﬁxation,  and  bone
arrow  plasmacytosis  less  than  1%.  A  third  whole  body  MRI
ith  diffusion-weighted  sequences  then  showed  complete
egression  of  the  lesions.  Following  this,  the  patient  was
aintained  in  complete  remission  with  continuation  of  the
enalinomide/dexamethasone  treatment,  after  10  months
ollow-up  (i—l).
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Figure 7. a: small left frontal lytic image in the spongy bone but discretely eroding the external layer; b: small punched out frontal
lacunae.
Figure 8. a: multiple costal lacunae eroding the cortical bone and image of intracortical resorption of the left humerus; b: images of
endosteal resorption of the cortical bone of the humerus; c: costal punched out lacunae.
Figure 9. a: left iliac wing lacunae with rupture of the cortical bone; b: left iliac wing with punched out lacunae.
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Figure 10. a: cortical lacunae and endosteal resorption in the femoral diaphyses; b: cortical lacunae and permeative appearance of the
femoral diaphyses.
Figure 11. Mr A. initial MRI performed on 01/09/2009 (a: T1-weighted, b: STIR, c: diffusion-weighted, d: STIR-diffusion-weighted fusion).
MRI performed after two courses of treatment (e, f, g, h). MRI after seven courses of treatment (i, j, k, l).
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Figure 12. Mrs R. MRI performed on diagnosis of MM on 30/09/2009 (a—d). MRI performed on 29/12/2009 following four courses of
 afte
S
o
w
3
r
ttreatment, showing progression of the lesions (e—h). MRI performed
time of relapse on 06/09/2010 (m—p).
Case  2
Mrs  R.’s  evolution  was  immediately  unfavourable  with  treat-
ment  (Fig.  12):  in  this  patient,  a  kappa  FLC  MM  complicated
by  plasma  cell  leukaemia  was  diagnosed  at  the  end  of
September  2009.  The  patient,  then  aged  62,  complained  of
bone  pain,  and  laboratory  results  revealed  the  presence  of
circulating  plasma  cells  and  hypogammaglobulinaemia  with
an  increase  in  kappa  FLC  (kappa/lambda  457.9).  Twenty-
four-hour  proteinuria  was  2.25  g,  composed  of  kappa  FLC.
o
I
t
cr the transplant showing stable lesions (i—l). MRI performed at the
tandard  X-ray  showed  the  presence  of  more  than  three
steolytic  lesions.  The  ﬁrst  whole  body  MRI  with  diffusion-
eighted  sequences  was  performed  on  diagnosis  of  MM,  on
0/09/2009,  and  found  moderate/severe  diffuse  bone  mar-
ow  inﬁltration  associated  with  focal  lesions  in  STIR  (less
han  5)  and  in  diffusion-weighting  (5  to  20)  (a—d).  A  ﬁrst  line
f  treatment  was  begun  with  bortezomib/dexamethasone.
n  the  haematological  re-evaluation  after  four  courses  of
reatment  the  patient  showed  a  VGPR  according  to  the  IURC
riteria.  A  second  whole  body  MRI  with  diffusion-weighted
182  R.  Duvauferrier  et  al.
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migure 13. Mrs O. MRI performed on diagnosis on 11/02/2009 (a—d
artial regression (e—h). Third MRI performed on 19/04/2010 conﬁr
equences,  performed  on  29/12/2009,  did  not  agree  with
he  laboratory  ﬁndings  as  it  showed  worsening  of  the  lesions
e—h).  The  ﬁrst  line  of  treatment  was  followed  by  autolo-
ous  stem  cell  transplantation  which  maintained  the  VGPR.
 third  whole  body  MRI  with  diffusion-weighted  sequences,
erformed  after  the  transplant,  showed  the  lesions  to  be
table  in  STIR  and  diffusion-weighting  but  worsening  with
1-weighting  (i—l).  The  patient  subsequently  relapsed  and
as  treated  with  lenalinomide/dexamethasone,  then  borte-
omib/doxorubicin,  then  bendamustine.  A  fourth  whole
ody  MRI  with  diffusion-weighted  sequences  was  performed
t  the  time  of  the  relapse,  on  06/09/2010  (m—p).  Despite
he  different  treatments  used,  it  was  not  possible  to  con-
rol  the  evolution  of  the  disease  and  the  patient  died  on
7/04/2011.
ase  3
his  case  concerned  Mrs  O.  who  had  had  a  relapse  fol-
owing  treatment  (Fig.  13):  this  71-year-old  patient  had
een  diagnosed  as  having  an  IgG  lambda  symptomatic  MM
n  February  2009.  She  had  no  functional  complaints  despite
naemia  of  7.8  g/dl.  A  PPE  found  a  monoclonal  peak  of
3  g/l,  shown  by  immunoﬁxation  to  be  an  IgG  lambda.  The
D
T
cI performed after eight courses of treatment (09/11/2009) showing
 disease progression (i—l).
yelogram  had  83%  plasma  cells.  No  osteolytic  lesion  was
een  on  the  standard  X-ray.  A  ﬁrst  whole  body  MRI  with
iffusion-weighted  sequences  was  performed  on  diagno-
is,  on  11/02/2009  (a—d),  and  found  severe  bone  marrow
nﬁltration,  with  no  focal  lesions.  Treatment  with  lenali-
omide/dexamethasone  produced  a PR  after  eight  courses
peak  of  18.5  g/l).  A  second  whole  body  MRI  with  diffusion-
eighted  sequences,  performed  on  09/11/2009,  also  found
artial  regression  of  the  lesions,  with  a  change  from  the
ppearance  of  diffuse  inﬁltration  to  that  of  focal  lesions
e—h).  After  this,  the  MM  evolved  under  treatment,  lead-
ng  to  the  prescription  of  a  second  line  of  treatment  with
elphalan/prednisone/thalidomide.  A  third  MRI  performed
n  19/04/2010  conﬁrmed  progression  of  the  disease,  with
he  reappearance  of  severe  diffuse  bone  marrow  inﬁltration
i—l).  Despite  three  other  poorly  tolerated  lines  of  treat-
ent,  the  patient  died  on  26/07/2011.isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
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